Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 18;40:75. doi: 10.1186/s13046-021-01877-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 4 — Expression and prognostic role of SRPKs in CAC. a RNA levels of upstream kinases targeting splicing factors in paired clinical specimens were tested by RT-qPCR (n = 32). P value was based on paired Student’s t-test. b Correlations between nucleus SRSF1 level and upstream kinases were analyzed via Spearman correlation test (n = 32). The nucleus SRSF1 level was scored by the specific nucleus staining of SRSF1 (ranging 0–12) without considering its cytosol staining. c Protein levels of SRPK1 and SRPK2 in paired clinical specimens were tested by western blotting (left panel). After semi-quantified, we found that 75% cases (24/32) showed increased SRPK1 in tumor tissues (middle panel), and 71.9% cases (23/32) exhibited increased SRPK2 (right panel). d Representative IHC results of SRSF1, SRPK1, and SRPK2 in specimens from validation cohort. Scale bar: 100 μm. e The different protein levels of SRPK1, SPRK2, and nucleus SRSF1 in validation cohort were exhibited by box plots according to IHC data. P value was based on unpaired Student’s t-test. f Patients with both high-SRPK1 and high-SRPK2 levels exhibited the highest nucleus SRSF1 level, while patients with low SRPK1 and low SRPK2 showed the lowest nucleus SRSF1 IHC score. P value was based on One-way ANOVA test. Kaplan-Meier survival curves showed the clinical relevance of nucleus SRSF1 (g), SRPK1 (h), and SRPK2 (i) in validation cohort of CAC patients, respectively. Furthermore, the higher expression of both SRPK1 and SRPK2 showed a more significant role on indicating poorer overall survival (j). Forest plots summarized the significant prognostic factors by univariate (k) and multivariate (l) analyses, the corresponding data were supplemented in Table S4 and Table S5. P value was calculated by log-rank test or Cox-regression test